Chest Infections SESSION TITLE: Respiratory Care SESSION TYPE: Original Investigation Slide PRESENTED ON: Tuesday, October 31, 2017 at 08:45 AM - 10:00 AM Within-Trial Cost Analysis of COPD Exacerbations From the Summit Clinical Outcomes Study of Fluticasone Furoate/Vilanterol Inhalation Richard Stanford* Anna Coutinho Michael Eaddy Binglin Yue and Michael Bogart GlaxoSmithKline, Research Triangle Park, NC PURPOSE: To assess the economic beneﬁts of treating COPD patients with cardiovascular (CV) risk using data from a large clinical outcomes study. METHODS: A retrospective economic analysis from the U.S. healthcare system payer perspective was conducted using withintrial data of the intent-to-treat population from the Study to Understand Mortality and Morbidity in COPD (SUMMIT). The objective of the economic analysis was to compare 1-year costs of on-treatment moderate/severe COPD exacerbations between each active treatment comparator, ﬂuticasone furoate 100 mcg/vilanterol 25 mcg (FF/VI), ﬂuticasone furoate 100 mcg (FF), and vilanterol 25 mcg (FF) versus placebo (PBO). Analysis: The total cost of COPD exacerbations were obtained by applying the unit cost estimates obtained from a large US managed care database to the number of events occurring during each patient’s follow-up. These unit costs were determined in a cohort of COPD patients with CV risk. Mean costs for COPD exacerbations were then computed for all the 4 treatment cohorts using inverse probability treatment weighting (IPTW) to account for censoring. The average duration of follow-up was 1.7 years; however the pre-deﬁned follow-up period of observation for estimation of costs was set at 1 year. Bootstrapping was performed to estimate 95% CI around the mean. The incremental mean cost difference from PBO was also estimated using the same boot strapping methods. CONCLUSIONS: The estimated cost of moderate/severe exacerbations in subjects with COPD and CV risk were lower for all treatments compared to no treatment within the SUMMIT trial. The cost reduction was greatest with FF/VI treatment. (GSK Study HO-15-15547). CLINICAL IMPLICATIONS: Clinicians and payers may be able decrease the cost of COPD care by effectively treating COPD in COPD patients with CV risk. DISCLOSURE: Richard Stanford: Employee: GSK, Shareholder: GSK Anna Coutinho: Employee: Xcenda, which received consulting fees to conduct the research Michael Eaddy: Employee: Xcenda, which received consulting fees to conduct the research Binglin Yue: Employee: Xcenda, which received consulting fees to conduct the research Michael Bogart: Employee: GSK, Shareholder: GSK No Product/Research Disclosure Information DOI: http://dx.doi.org/10.1016/j.chest.2017.08.214 Copyright ª 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. chestjournal.org 183A CHEST INFECTIONS RESULTS: A total of 16 485 subjects were evaluated (4111 PBO, 4121 FF/VI, 4118 VI and 4135 FF) were assessed, average age of 65 years of age and about 75% male. Mean 1-year cost of moderate/severe exacerbations were signiﬁcantly lower (p<0.001) for FF/VI ($2468, 95% CI, $2158, $2792), FF ($2592, 95% CI, $2302, $2900) and VI ($2708, 95% CI, $2392, $3073) compared to PBO ($3386, 95% CI, $3015, $3792). Mean difference in 1-year cost from PBO for moderate/severe exacerbations were FF/VI: $981 (95% CI, $934, $902), FF: $794 (95% CI, $810, $779), and VI: $678 (95% CI, $694, $662).